We previously reported that the class I and II HDAC inhibitors TSA and Quisinostat (JNJ) have potential for use in therapy for lung adenocarcinoma via changes in the expression of angulin-1/LSR and CLDN-2 [39]. This evidence concerns the gene CLDN2 and lung adenocarcinoma.